Chronic diabetes conditions include type 1 diabetes and type 2 diabetes. Potentially reversible diabetes conditions include prediabetes and gestational diabetes. Prediabetes occurs when your blood sugar levels are higher than normal, but not high enough to be classified as diabetes. And prediabetes is often the precursor of diabetes unless appropriate measures are taken to prevent progression. Gestational diabetes occurs during pregnancy but may resolve after the baby is delivered.
May 2nd 2024
The current study highlights the potential benefit of incorporating continuous glucose monitor (CGM) data into eye care assessments for patients with type 1 diabetes (T1D).
The Emerging Treatment Landscape for Hemophilia A and the Valuable Role of the Specialty Pharmacist
1.5 Credits / Endocrinology Diabetes & Metabolism
View More
Improving Pharmacists' Knowledge of Endometrial Cancer and Solutions for Equity and Medication Access
1.5 Credits / Endocrinology, Diabetes & Metabolism, Oncology
View More
Delving Into the Latest Integrated Continuous Glucose Monitoring Devices: An Interdisciplinary Approach With Case Discussions to Enhance Diabetes Care
1.5 Credits / Endocrinology Diabetes & Metabolism
View More
Delving Into the Latest Integrated Continuous Glucose Monitoring Devices: An Interdisciplinary Approach With Case Discussions to Enhance Diabetes Care (Pharmacy Technician Cre...
1.5 Credits / Endocrinology Diabetes & Metabolism
View More
Diabetes Management With Integrated Continuous Glucose Monitoring Devices: Pharmacist Best Practices for Individualizing Treatment
0.75 Credit / Endocrinology Diabetes & Metabolism
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
The Role of Integrated Continuous Glucose Monitoring in Improving Clinical Outcomes in Diabetes
0.75 Credit / Endocrinology Diabetes & Metabolism
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Continuous Glucose Monitoring in Diabetes Care: Examining the Value and Addressing Barriers to Access
3.5 Credits / Endocrinology, Diabetes & Metabolism
View More
Introduction to Chronic Kidney Disease in People Living With Type 2 Diabetes: Combating Disease Progression and Complications
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Examining Current and Emerging Therapies to Slow Progression of Chronic Kidney Disease
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Tailoring Recommendations for People Living With Type 2 Diabetes and Chronic Kidney Disease: The Role of the Pharmacist
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney Disease
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Does Tirzepatide's Benefits in Patients with Type 2 Diabetes Make The Price Worth It?
April 12th 2023Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight when compared to semaglutide. But with a current list price of $1,023 for a one-month supply, is tirzepatide (Mounjaro; Lilly) worth it?
Promoting Health Equity and Achieving Pharmacoequity to Ensure Medication Access for All
March 27th 2023Speakers at the 2023 virtual Value-Based Insurance Design Summit discussed government programs and company initiatives to advance health equity, as well as the role of research and advocacy to achieve pharmacoequity.
Patients With Diabetes Taking Pioglitazone Less Likely to Develop Dementia
February 20th 2023Not only were people with newly diagnosed type 2 diabetes less likely to develop dementia if they took pioglitazone, but the benefit was stronger among patients with a history of ischemic heart disease or stroke.
Phase 3 Trial Shows Benefit of Empagliflozin for Pediatric Type 2 Diabetes
December 22nd 2022Eli Lilly and Company and Boehringer Ingelheim announced their SGLT2 inhibitor, empagliflozin, was associated with statistically significant reductions in HbA1c relative to placebo therapy among a population of pediatric patients with type 2 diabetes in the DINAMO trial.